Key Highlights

  • Propanc shares are trading down 3.19% at $1.78, against a previous close of $1.84.
  • PRP reduced proliferation by about 50%, and the galunisertib combination by 66% to 75%.
  • An Australian Patent application was filed for the combination approach.

Propanc (NASDAQ:PPCB) shares are trading down 3.19% at $1.78, against a previous close of $1.84, after the company reported new preclinical findings for its pancreatic proenzyme formulation, PRP, alone and combined with a TGF-beta inhibitor in pancreatic cancer models. The stock trades below $5, which makes it a penny stock, and Volume is light at about 20,560 shares.

Propanc is a pre-revenue biotechnology company based in Australia and founded in 2007. It develops proenzyme-based therapies to prevent cancer recurrence and metastasis in pancreatic, ovarian and colorectal cancers by targeting cancer stem cells. Its lead candidate, PRP, now called PPC-001, is an intravenous combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen.

How the Study Was Run

The research was carried out with investigators at the Universities of Jaén and Granada in Spain. It compared PRP, galunisertib, a small-molecule inhibitor of TGF-beta receptor I, and the two together in pancreatic ductal adenocarcinoma models. These included wild-type BxPC-3 cells, gemcitabine-resistant BxPC-3 cells, normal-associated fibroblasts and cancer-associated fibroblasts.

Pancreatic cancer is shaped by interactions between malignant cells and the surrounding tumor microenvironment, and TGF-beta signaling can contribute to tumor-cell plasticity and stromal activation. The study asked whether PRP could change these processes and whether adding a TGF-beta pathway inhibitor added further effects.

Key Preclinical Findings

PRP reduced cell proliferation by about 50% in both wild-type and gemcitabine-resistant cells compared with untreated controls, while PRP plus galunisertib reduced proliferation by 75% and 66%. The extra reduction from the combination was significant in wild-type cells but not in resistant cells. PRP cut colony formation by 59% in wild-type and 39% in resistant cells, and the combination by 68% and 64%.

In wound-healing assays at 72 hours, wound closure was 21% with PRP in wild-type cells and 57% in resistant cells, compared with untreated controls, and 19% and 30% with the combination, which improved on PRP alone in resistant cells but not in wild-type cells.

In Matrigel invasion assays, PRP reduced invasion by 81% in wild-type and 47% in resistant cells, and the combination by 89% and 80%. PRP also lowered transcript levels of SMAD2, SMAD3 and TGFBR1, raised E-cadherin expression by more than fourfold, and reduced Vimentin and Snail, markers linked to tumor-cell plasticity. The company said the added effect of the combination varied across models and markers.

Patent Filing and Next Steps

Propanc has filed an Australian patent application covering the combination approach. Its chief executive said the collaboration provides scientific evidence and a rationale for giving PRP as a stand-alone therapy and in combination with inhibitor drugs, which can be limited by resistance mechanisms over time. He said PRP works by altering the behavior of malignant cells rather than by inhibition, and that the company expects further announcements on preparatory work for its Phase 1b first-in-human study.

These results come from laboratory models, and they do not show how PRP will perform in patients. The stock sits at its 52-week low of $1.78 and the company has only two full-time employees, so progress to the clinic and the funding needed for it will be the main drivers of the share price. The key points to watch are the start of the Phase 1b study and any further data on the combination.